<p>Madrigal Pharmaceuticals (NASDAQ:MDGL) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $761.6, a high estimate of $964.00, and a low estimate of $529.00. This current average has increased by 38.66% from the previous average price target of $549.25. </p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="price target chart" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png"/></p>

<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Madrigal Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Hammond</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$529.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$964.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$745.00</td>
<td>$527.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$900.00</td>
<td>$540.00</td>
</tr>
<tr>
<td>William Woods</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$670.00</td>
<td>$560.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Madrigal Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Madrigal Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Madrigal Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Madrigal Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p>Stay up to date on Madrigal Pharmaceuticals analyst ratings.</p>
<h2>Unveiling the Story Behind Madrigal Pharmaceuticals</h2>
<p>Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.</p>
<h3>Madrigal Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Madrigal Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>362.03%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Madrigal Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-39.75%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Madrigal Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-17.28%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Madrigal Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-9.6%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Madrigal Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.55</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

ARKG

<p>Madrigal Pharmaceuticals (NASDAQ:MDGL) has received mixed ratings from 5 analysts over the past three months, with an average 12-month price target of $761.6, up 38.66% from $549.25. Recent actions include a downgrade to Neutral by B of A Securities and upgrades to Overweight by Barclays and Piper Sandler. The company, focused on treatments for metabolic dysfunction-associated steatohepatitis, has shown significant revenue growth of 362.03% but faces challenges with low return on equity and assets. Analysts' ratings reflect their evolving expectations based on market conditions and company performance.</p>

benzinga_article

Ark Genomic Revolution ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Global Healthcare

iShares Biotechnology ETF

Madrigal Pharma

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Health Care Select Sector SPDR

ALPS Medical Breakthrough

SPDR S&P Biotech

Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)